

Product Data Sheet

EEKLIVVAF

Cat. No.: HY-P3644 CAS No.: 188818-21-5 Molecular Formula: $C_{50}H_{82}N_{10}O_{14}$ Molecular Weight: 1047.24

EEKLIVVAF Sequence Shortening: Target: Others

Pathway: Others

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

BIOLOGICAL ACTIVITY

Description	EEKLIVVAF is a pepitide, can be recognized on HLA-B44 by the anti-melanoma cytolytic T-cell (CTL) clone LB33- CTL-159/5 ^[1]
In Vitro	EEKLIVVAF can be recognized by CTL clone on C1RB*4402 and C1R-B*4403 cells, and (45 ng/mL and 160 ng/mL, respectively; 30 min; 20 🛭) shows the ability to compete with a standard peptide for binding to HLA-B*4402 and HLA-B*4403 molecules ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Herman J, et al. Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid. Tissue Antigens. 1999 Feb;53(2):111-21.

[2]. Herman J, et al. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics. 1996;43(6):377-83.

[3]. Herman J, et al. Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid. Tissue Antigens. 1999 Feb;53(2):111-21.

[4]. Coulie PG, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7976-80.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Inhibitors

Screening Libraries

Proteins

Page 1 of 1